TRIB — Trinity Biotech Share Price
0.000.00%
Last trade - 00:00- $2.76m
- $53.93m
- $56.83m
- 29
- 68
- 31
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.05 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -60.91% | ||
| Return on Equity | n/a | ||
| Operating Margin | -47.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 90.44 | 101.98 | 92.97 | 62.52 | 56.83 | 67 | 73.5 | -10.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -44.86 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Trinity Biotech PLC is an Ireland-based develops, acquires, manufactures and markets medical diagnostic systems, including both reagents and instrumentation for the clinical laboratory and point-of-care segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Its segments include the Americas and Rest of World. It is a provider of raw materials to the life sciences and research industries globally. It also operates a licensed reference laboratory that specializes in diagnostics for autoimmune diseases. Its POC brands include Uni-Gold, Recombigen, MarDx, FlexTrans, Premier and Ultra. Its clinical laboratory brands include ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ. The Company manufactures kits for the detection of specialty and esoteric biomarkers of infectious diseases and other associated laboratory products.
Directors
- Ronan O'Caoimh CHM (65)
- John Gillard CFO (40)
- Fernando Devia EVP (58)
- Sanjiv Suri SVP (62)
- Simon Dunne CAO (47)
- Eibhlin Kelly CIO (37)
- James Walsh EDR (62)
- Terence Dunne OTH (40)
- Kevin Tansley DRC (50)
- Clinton Severson NED (72)
- James Merselis NID (67)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 22nd, 1992
- Public Since
- October 21st, 1992
- No. of Employees
- 398
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 30,566,056.8
- Address
- Ida Business Park, BRAY, 18
- Web
- https://www.trinitybiotech.com/
- Phone
- +353 12769800
- Contact
- Eric Ribner
- Auditors
- Grant Thornton
Upcoming Events for TRIB
Similar to TRIB
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Trinity Biotech share price?
As of Today at 19:23 UTC, shares in Trinity Biotech are trading at $1.81. This share price information is delayed by 15 minutes.
How has the Trinity Biotech share price performed this year?
Shares in Trinity Biotech last closed at $1.81 and the price had moved by -68.33% over the past 365 days. In terms of relative price strength the Trinity Biotech share price has underperformed the S&P500 Index by -73.64% over the past year.
What are the analyst and broker recommendations for Trinity Biotech?
The overall consensus recommendation for Trinity Biotech is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Trinity Biotech dividend yield?
Trinity Biotech does not currently pay a dividend.
Does Trinity Biotech pay a dividend?
Trinity Biotech does not currently pay a dividend.
When does Trinity Biotech next pay dividends?
Trinity Biotech does not currently pay a dividend.
How do I buy Trinity Biotech shares?
To buy shares in Trinity Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Trinity Biotech?
As of the previous close price of $1.81, shares in Trinity Biotech had a market capitalisation of $2.76m.
Where are Trinity Biotech shares listed?
Here are the trading details for Trinity Biotech:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TRIB
What kind of share is Trinity Biotech?
Based on an overall assessment of its quality, value and momentum Trinity Biotech is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Trinity Biotech share price forecast for 2024?
The analyst consensus target price for shares in Trinity Biotech is $3.00. That is 66.17% above the last closing price of $1.81.
Analysts covering Trinity Biotech currently have a consensus Earnings Per Share (EPS) forecast of -$0.30 for the next financial year.
What is the trend in the Trinity Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Trinity Biotech. Over the past six months, its share price has underperformed the S&P500 Index by -36.14%.
As of the last closing price of $1.81, shares in Trinity Biotech were trading -36.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Trinity Biotech PE Ratio?
The Trinity Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.81.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Trinity Biotech?
Trinity Biotech's management team is headed by:
- Ronan O'Caoimh - CHM
- John Gillard - CFO
- Fernando Devia - EVP
- Sanjiv Suri - SVP
- Simon Dunne - CAO
- Eibhlin Kelly - CIO
- James Walsh - EDR
- Terence Dunne - OTH
- Kevin Tansley - DRC
- Clinton Severson - NED
- James Merselis - NID